



Does *Helicobacter pylori* protect against asthma and allergy?

Martin J Blaser, Yu Chen and Joan Reibman

Gut 2008;57;561-567; originally published online 14 Jan 2008;
doi:10.1136/gut.2007.133462

Updated information and services can be found at:
<http://gut.bmj.com/cgi/content/full/57/5/561>

These include:

References

This article cites 70 articles, 32 of which can be accessed free at:
<http://gut.bmj.com/cgi/content/full/57/5/561#BIBL>

Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Notes

To order reprints of this article go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to *Gut* go to:
<http://journals.bmj.com/subscriptions/>

Does *Helicobacter pylori* protect against asthma and allergy?

Martin J Blaser,^{1,2,3} Yu Chen,^{1,4} Joan Reibman^{1,4}

The microbes that persistently colonise their vertebrate hosts are not accidental.¹ Although highly numerous and diverse, there is specificity by site and substantial conservation between individuals. The genus *Helicobacter* includes spiral, highly motile, urease-positive, Gram-negative bacteria that colonise the stomach in many mammals. Each mammal has one or more dominant *Helicobacter* species and they are highly, if not exclusively, host species-specific.² Such observations are consistent with the hypothesis that when ancestral mammals diverged from reptiles about 150 million years ago, they contained ancestral helicobacters, which then diverged as their hosts changed. According to this hypothesis, helicobacters represent ancestral biota (flora) in the mammalian stomach. The human-adapted strain is *H pylori*,³ which has not been reproducibly observed in any animals other than humans and other primates.³

Although we can not reliably estimate how long *H pylori* has been in the human stomach, its ancestors may have been present when our humanoid ancestors diverged from other primates about four million years ago. Consistent with this view are results from phylogeographic studies; strong and consistent evidence indicates that our ancestors already were carrying gastric *H pylori* when a group that ultimately populated much of the world last left Africa, more than 58 000 years ago.⁴ In any case, *H pylori* has been colonising the stomach of humans since at least Paleolithic times.

In this paper, we examine the evidence concerning the relationship of this ancient member of the human microbiota, and particularly its absence, with the recent and on-going epidemic of asthma and related allergic disorders. We discuss the possibility that gastric *H pylori* colonisation

protects against these disorders and that its disappearance has fuelled their rise.

H PYLORI ACQUISITION AND PERSISTENCE

H pylori is acquired, and may be detected, in early childhood usually after the first year of life.⁵ Transmission is faecal-oral, oral-oral and vomitus-oral.⁶ Once acquired, in the absence of antibiotic use, *H pylori* persists at least for decades, and most often for the full life of its host.⁷ *H pylori* strains are highly variable, and several loci affect *H pylori*-host interactions. In particular, strains with an intact *cag* island inject the CagA protein into host gastric epithelial cells;⁸ this heightened interaction in relation to *cag*-negative strains affects disease risk.^{9–10}

For most of human existence, we have lived in small, intimate groups,¹¹ in which our microbiota mingled extensively with that of other group members.¹² Under the conditions of poor hygiene that have predominated for most of human existence, transmission of gastro-intestinal microbes has been easily accomplished. In present-day developing countries in which such enteric transmission occurs, *H pylori* is ubiquitous, with estimates for its prevalence in adults exceeding 80%; its presence is possibly nearly universal, when multiple detection methods are used.^{7–13} In populations in which *H pylori* is highly prevalent, gastric colonisation with several distinct strains appears common.¹⁴

H PYLORI IS DISAPPEARING

Despite the substantial evidence for the antiquity and ubiquity of *H pylori* colonisation in humans, it now has become clear that the prevalence of *H pylori* is rapidly decreasing! This is a birth cohort effect, which began in the early 20th century in many developed countries, and accelerated after World War II.^{15–17} The effect has been so profound that fewer than 10% of children under 10 in the United States and in other industrialised countries now are *H pylori*-positive, compared to the historic 70–90% levels.^{15–17} As a result of this change, occurring around the developed world to variable extents,

risk factors for *H pylori* acquisition can be determined. These include large family size, having parents (especially mothers) carrying *H pylori*, *H pylori*-positive older siblings, and household crowding during childhood.^{18–19} Thus, as disappearance begins, the effects compound with each generation, especially as water has become cleaner, family sizes have shrunk, mothers pre-masticate food less, and nutrition has improved.²⁰

Another phenomenon that may contribute to *H pylori* disappearance is the widespread use of antibiotics, especially during childhood.²¹ To reliably eradicate *H pylori* requires combinations of two to four antimicrobial agents, but early studies with monotherapies, including beta-lactam and macrolide antibiotics, showed eradication rates from 10 to 50%.^{22–23} If comparable effects occur every time a child is treated with antibiotics for an upper respiratory or skin infection or for otitis media, then the rapid (and compounding) decline in *H pylori* prevalence in childhood in developed countries in recent decades is not difficult to understand.

CONSEQUENCES OF THE PRESENCE OR ABSENCE OF *H PYLORI*

By comparing persons with and without the organism, medical scientists have studied the costs and benefits of carrying *H pylori*. First came the observation that the presence of *H pylori* in the gastric lumen is associated with the presence in the gastric lamina propria of phagocytic and immune cells.²⁴ Warren and Marshall recognised the association of *H pylori* with these histological findings, which pathologists call “chronic gastritis”;^{24–25} the presence of inflammatory cells leads to use of terms implying pathological processes. However, as biologists, we believe that the collection of immune and inflammatory cells in the tissue should be considered as “the physiological response to the indigenous microbiota” (or PRIM). Similarly, the lamina proprias of the mammalian mouth, vagina and colon are populated by phagocytic and immunological cells that respond to the local indigenous microbiota. In contrast, germ-free animals have essentially no phagocytic and immune cells in their lamina propria, but “conventionalising” these animals, by restoring their normal biota restores these cells, which is considered as the normal histopathology.²⁶

One difficulty with terming the host response to *H pylori* as “chronic gastritis” is not in the observation, which is correct,

¹ Department of Medicine, New York University School of Medicine, New York, USA; ² Department of Microbiology, New York University School of Medicine, New York, USA; ³ Medical Service, New York Harbor Veterans Affairs, Medical Center, New York, USA; ⁴ Department of Environmental Medicine, New York University School of Medicine, New York, USA

Correspondence to: Dr Martin J Blaser, Department of Medicine, 550 First Avenue OBV A606, New York, NY 10016, USA; martin.blaser@med.nyu.edu

but in interpreting the finding as pathological, and not as physiological. However, in at least one context PRIM also is pathological, since it is associated with increased risk for development of peptic ulceration,^{27 28} and gastric adenocarcinoma and lymphoma.^{10 29} Further, the highly interactive CagA-positive strains induce the strongest PRIM and confer the greatest risk of ulceration and carcinoma.^{10 28 30} Thus, *H pylori* and the PRIM it induces are clearly associated with risk of disease, and even fatality. The decline in the incidence of these diseases in the 20th century is consistent with the decline in *H pylori* prevalence.

However, it now has become clear that there is an inverse association between *H pylori* and reflux oesophagitis (GORD), and its consequences, including Barrett's oesophagus, and oesophageal adenocarcinoma.¹⁰ Although the gastric PRIM is a risk factor for the development of peptic ulceration and gastric adenocarcinoma, it is inversely associated with the development of these oesophageal diseases, and the more interactive CagA-positive strains are associated with the strongest inverse effects.¹⁰ Thus, a paradigm exists of a host-microbial interaction that in some cases may promote pathological conditions, whereas in other cases may be protective from pathology. This is not a simple concept for most physicians, but in fact fits well with Rosebury's definition of an "amphibiont" as a microbe that could be pathogen or symbiont, depending on context.³¹ The phenomenon of "amphibiosis" can be used to characterise our indigenous microbiota,³² in which, for example, residential oral alpha-haemolytic streptococci protect against oral invaders, but also can cause endocarditis.

EFFECTS OF *H PYLORI* ON HUMAN PHYSIOLOGY

The stomach is an organ with multiple functions; *H pylori* and its induced PRIM affects at least three of these. First, the stomach secretes acid, which is under complex regulatory control, involving autonomic innervation, and the neuropeptide hormones, gastrin and somatostatin. It is evident that *H pylori* status affects this homeostasis.⁹ Second, the stomach has adaptive immunological activity in terms of both T and B cell function.³³⁻³⁷ The *H pylori*-positive and the *H pylori*-free stomachs are immunologically different, not only in terms of *H pylori*-specific responses,³⁶ but in more general responses as well,³⁷ and including a far greater population of regulatory T cells.³³⁻³⁵ Third, the stomach produces

leptin, and is the major site for production of ghrelin.⁹ These neuropeptide hormones play important roles in mammalian energy homeostasis, and emerging evidence indicates that *H pylori* status is relevant to their regulation.^{38 39}

It thus becomes clear that a generation or more of children in developed countries have been growing up without *H pylori* to guide or influence these physiological functions, and others not yet described (fig 1). It is predictable that such altered acid secretion, immunological activation, and neuropeptide regulation have a variety of consequences.

ASSOCIATION WITH ASTHMA AND ALLERGIC CONDITIONS?

In recent years, there has been a rise in the prevalence of asthma, hay fever (allergic rhinitis) and atopy (including eczema) in developed countries.⁴⁰ This change, which begins in early childhood, is present across many populations in the world, and is considerable in its extent. A perturbation of such magnitude must be environmentally caused, and some of the leading candidates include exposure to tobacco smoke, air pollution, allergens, exogenous infections and microbial substances in the environment, as well as obesity.⁴⁰⁻⁴²

In addition to these exogenous causes, an alternative hypothesis could relate to a change in our indigenous microbiota.¹ As such, it is plausible to consider *H pylori*, since its well-documented disappearance is extensive and involves developed country populations.¹⁵⁻¹⁷ Further, the disappearance of *H pylori* has preceded the rise in asthma, but are they related?

Tables 1 and 2 summarise 12 recent cross-sectional and four case-control studies, respectively, in which the relationships of *H pylori* with asthma, atopy, allergic rhinitis, and/or eczema were examined.⁴³⁻⁵⁷ In general, the cross-sectional studies, involving a variety of populations and somewhat differing definitions of atopy and asthma, show significant inverse relationships of these conditions with *H pylori*. The published case-control studies, in general much smaller in scale, do not show any significant direct or inverse relationships (table 2). However, a case-control study we conducted in New York showed an inverse relationship between *H pylori*, especially *cagA*+ strains, with asthma and atopy.⁵⁸

To consider the findings of the cross-sectional analyses, we focus on two other studies that we conducted.^{51 54} We first examined a large, publicly available database from the National Health and

Nutrition Survey (NHANES) III, conducted between 1988 and 1994.⁵⁹ In the mid-1990s, *H pylori* and CagA serology were performed on stored specimens from more than 10 000 NHANES III subjects, with the laboratory workers and statisticians blinded to asthma or atopy status. In 2006, we were able to link 7663 records that contained information on both asthma and *H pylori* status.⁵¹ For all subjects, there was an inverse association of ever having had asthma with having a *cagA*+ *H pylori* strain [OR (95% CI) = 0.79 (0.63 to 0.99)], with a stronger inverse association in those less than the median (43 years) age [0.63 (0.43 to 0.93)], and no association in the older persons. Similarly, the inverse association was strongest in those who had asthma onset before the age of 15 years [0.63 (0.43 to 0.93)], with no association with those with older-onset asthma. Highly similar trends were observed in relation to allergic rhinitis and allergy symptoms, with some inverse relationships also occurring in persons with *cagA*-negative *H pylori* strains. We also linked records for 2386 persons who had skin tests performed for pollens and moulds, and who had *H pylori* status ascertained.⁵¹ For four of the six antigens tested, there were inverse associations in persons with *cagA*+ strains, especially those below the median age. Thus, we found inverse associations between *H pylori*, especially *cagA*+ strains, with asthma and related allergic disorders, especially involving younger individuals, and with early life disease onset.

Because of these findings, we sought independent assessment of the relationships. We then examined the subsequent survey, NHANES 1999-2000.⁶⁰ For that study, we found 7412 subjects who had data on asthma and related conditions as well as on *H pylori* status; no testing for *cagA* status had been performed. The median age in this study was 25, and because our prior results highlighted asthma with early age of onset, we focused on patients less than 20 years old. We found significant inverse associations of *H pylori* positivity with early onset of asthma and allergic rhinitis in children and teens under 20, as well as ever having had asthma and current asthma in children 3-13 years old.⁵⁴ *H pylori* also was inversely related to having recently had wheezing, allergic rhinitis, and dermatitis, eczema or rash. These two large, cross-sectional, independent studies show highly consistent results across asthma and related allergic disorders, and extend the prior studies which were more limited in sample size, age range of study

Table 1 Cross-sectional studies showing an association between *H pylori* and asthma, allergic rhinitis and atopic disease

Author, year (reference)	Location	Study population	Age (years)	<i>H pylori</i> measure	Definition of outcome	Major findings: Condition and OR (95% CI) in relation to <i>H pylori</i> +
Matricardi, 2000 (43)	Caserta, Italy	1659 Italian male military cadets	17–24	IgG ELISA	Total IgE Atopy: logRU > 1.2 Non-atopy: logRU < 0 Atopy: any IgE > 0.35 IU/ml	Atopy For <i>H pylori</i> , <i>T gondii</i> , Hep A 1 v 0 2 or 3 v 0 Atopy In 1973: In 1994: Asthma: Allergic rhinitis: Eczema: Any of the three: Atopy Allergic rhinitis: Hay fever/nasal allergies: Wheeze with no cold: Allergy to grass: Allergy to > 1 allergens: Atopy: Atopy, in Russians: In Finns: Atopy: For IgG antibodies to ≤ 3 specified infectious Atopy: Allergic asthma: Allergic rhinitis: OR in relation to CagA+, Ever asthma: Onset age ≤ 15: Eczema: Any allergic disease: Ever asthma: (in ≤ 19 years) Current asthma: (in ≤ 13 years) Early childhood: (onset < 5 years)
Kosunen, 2002 (44)	Vammala, Finland	326 and 319 healthy subjects in 1973 and 1994, respectively	15–54	IgA & IgG ELISA		0.70 (0.52 to 0.94)* 0.37 (0.22 to 0.63)* 0.97 (0.46 to 2.05) 0.20 (0.05 to 0.71)* 0.78 (0.59 to 1.05) 0.60 (0.36 to 1.00)* 0.29 (0.06 to 1.26) 0.70 (0.54 to 0.91)* 0.78 (0.57 to 1.08) 0.74 (0.51 to 1.07)
McCune, 2003 (45)	Bristol, UK	3244 healthy subjects	20–59	¹³ C-urea breath test	Current medications for the disorders: asthma (inhalers), allergic rhinitis (antihistamines), and eczema (topical corticosteroids)	
Linneberg, 2003 (46)	Denmark	1101 subjects	15–69	IgG ELISA	Self-reported allergic rhinitis Specific IgE to 6 allergens Atopy: any IgE > 0.35 kU/l	
Jarvis, 2004 (47)	East Anglia, UK	907 randomly invited from 15,000 young adults	20–44	IgG ELISA	Self-reported symptoms in the prior year suggestive of hay fever and asthma	1.01 (0.70 to 1.52) 0.80 (0.51 to 1.24) 0.65 (0.43 to 0.99)* 1.13 (0.81 to 1.59) 0.70 (0.39 to 1.28)
Radon, 2004 (48)	Northern Germany	321 with blood samples from 930 randomly selected from 3112 inhabitants	18–44	IgG ELISA, IgG CagA	Specific IgE against a panel of aeroallergens Atopy: any IgE > 0.70 kU/l	
von Hertzen, 2006 (49)	Eastern Finland, Western Russia	Healthy adults; 790 from Finland, 387 from Russia	25–54	IgG ELISA	Skin prick testing with a panel of 11 common airborne allergens Atopy: any wheal diameter ≥ 3 mm Detection of specific Atopy: any IgE > 0.35 kU/l	0.55, p < 0.01** 0.72, p = 0.53† 0.57 (0.43 to 0.77)* 0.70 (0.52 to 0.94)* 0.55 (0.34 to 0.89)* 0.59 (0.42 to 0.83)* 0.79 (0.63 to 0.99)* 0.63 (0.43 to 0.93)* 0.37, p < 0.01** 0.60 (0.40 to 0.90)* 0.65 (0.45 to 1.06) 0.41 (0.24 to 0.69)* 0.58 (0.38 to 0.88)*
Janson, 2007 (50)	Iceland, Sweden, Estonia	1249 healthy adults	Mean 42	IgG ELISA	Self-reported hay fever, asthma in the prior year Self-reported asthma and hay fever (current and lifetime)	
Chen, 2007 (51)	USA	7663 adults	20–90; Mean, 43	IgG ELISA, IgG CagA	Skin sensitisation tests Lifetime physician-diagnosed eczema Self-reported atopic dermatitis, bronchial asthma, allergic rhinoconjunctivitis, urticaria Self-reported asthma and hay fever (current and lifetime)	
Herbarth, 2007 (52)	Germany	2487 children	Mean 6	¹³ C-urea breath test		
Shiotani, 2007 (53)	Japan	777 university students	Mean 19	IgG ELISA		
Chen, 2007 (54)	USA	7412 adults	3–85; Mean 25	IgG ELISA		

*p < 0.05.

†CI was not estimated because information on covariates is not available; the study reported a p-value adjusted for covariates only.

Leading article

populations, as well as data on potential confounders, *H pylori* strains, and age of onset of asthma (table 1).

BIOLOGICAL PLAUSIBILITY FOR *H PYLORI* TO PLAY A PROTECTIVE ROLE AGAINST ASTHMA

H pylori status could be causally related to asthma and its related disorders, with colonised persons having a partial protection. Considering the Bradford Hill criteria⁶¹ provides evidence that supports such a causal role.

First, the secular trend is consistent and reverse causation is not likely; *H pylori* is disappearing while asthma incidence is rising. Importantly, the decline in *H pylori* acquisition, beginning early in the 20th century, precedes the increase in asthma. However, all of the epidemiological studies to date are cross-sectional or case-control studies, and not prospective. Nevertheless, it is not likely that asthma and related disorders could themselves be leading to the disappearance of *H pylori*. Once acquired early in life, if not treated with antibiotics, *H pylori* persists at least for decades, if not for life. The cross-sectional studies could measure an effect of asthma, or of its treatment. For example, if asthmatics receive more antibiotics than non-asthmatics, *H pylori* prevalence could be reduced. However, the specificity of the inverse association with early life asthma and not with long-standing asthma seen in adults is one argument against that proposition.

Second, a dose-response relationship between exposure and disease is present. Studies of differences among *H pylori* strains show the strongest effects for *cagA*+ strains, in terms of risk of disease (ulcers, gastric cancer) or protection from disease (GORD and oesophageal adenocarcinoma). A similar dose-response to that related to GORD is present with

asthma, with *cagA*+ strains having the strongest inverse association.^{54 58}

Third, as shown in table 1, a variety of cross-sectional studies show protective effects, suggesting consistency of the data. The increasing number of these studies, especially our two large, independent, and population-based studies, point toward a correct association. Nevertheless, that not all studies, especially the case-control studies (table 2), show this inverse association could indicate that there is population-based specificity for the observation, and/or differences in study design.

Fourth, is the role of specificity; asthma is considered as predominantly allergic or not. The strong inverse associations with *H pylori* are present for asthma and other allergic disorders consistent with the allergic (atopic) spectrum. In addition, the inverse association with *H pylori* appears stronger for childhood-onset asthma. There may be aetiological differences between childhood-onset and adulthood-onset asthma. Childhood asthma often remits during adolescence, although many of these patients in remission have relapses during young adulthood.⁶² Consistently, the case-control studies of *H pylori* and current asthma in adults did not find any association (table 2). The effect of *H pylori* may be less important in adult-onset asthma, since the risk factors may be much more heterogeneous than in childhood asthma. In addition, asthma in adults may be new onset, persistent from childhood, or exacerbated from childhood asthma. Although commonly associated with atopy, adult asthma is more complex and onset may be complicated by environmental exposures (e.g. tobacco, occupation).^{63 64} Finally, the misclassification of current status of asthma and *H pylori* could be more serious in adults. Since the misclassifications of asthma and *H pylori* status do not depend on one another, it is

non-differential, which would lead to a bias toward the null.

Fifth, the inverse association is coherent with our knowledge, and there is no evidence of plausible competing theories or rival hypotheses. One possibility is that *H pylori* status, while related to asthma risk, is merely a marker for other phenomena. For example, early life antibiotic use^{65 66} that eliminates *H pylori* carriage also could eliminate one or more other microbes that actually are the protective agents. There are insufficient data at present to rule out this possibility. Several studies that have evaluated multiple infections suggest their additive effect in the aetiology of asthma^{43 50} (table 1). In addition, the inverse association between *H pylori* and asthma is independent of indicators of socioeconomic status, age, gender, ethnic background, smoking status and hepatitis A infection.⁵¹ An independent phenomenon that makes asthma more likely and *H pylori* carriage less likely could be underlying the inverse association. Such a phenomenon could be due to enhancement of Th-2 immunity induced by another microbe, for example, and a consequent effect on *H pylori* status could provide a marker of risk.


Sixth, mechanisms exist (see below) that could explain a protective effect. In total, there is considerable biological plausibility for a protective role of *H pylori* (especially *cagA*+) strains toward asthma and related disorders.

MECHANISMS BY WHICH GASTRIC *H PYLORI* COLONISATION MIGHT AFFECT ASTHMA RISK

In the simplest statement, it is increasingly clear that the gastric physiology of the *H pylori*-positive and negative subjects differs.^{9 20 67} Several non-exclusive mechanisms could be playing a role.

Table 2 Case-control studies showing an association between *H pylori* and asthma, allergic rhinitis and atopic disease

Author, year (reference)	Location	Study population	Age (years)	<i>H pylori</i> measure	Definition of outcome	Major findings: Condition and OR (95% CI) in relation to <i>H pylori</i> +
Matricardi, 2000 (43)	Caserta, Italy	240 atopic cases and 240 non-atopic controls	17–24	IgG ELISA	Total IgE Atopy: logRU >1.2 Non-atopic: logRU <0	Atopy: 0.76 (0.47 to 1.24)
Bodner, 2000 (55)	Grampion, Scotland	97 cases and 208 controls	39–45	IgG ELISA	Skin & specific IgE tests Atopy: weal ≥3 mm, or any IgE >0.35 IU/ml Self-reported adult-onset wheeze and asthma	Wheeze: 1.20 (0.70 to 2.20) Wheeze and asthma: 0.50 (0.20 to 1.50) Atopy: 0.90 (0.60 to 1.60)
Tseng, 2000 (56)	Hong Kong	90 cases with stable asthma and 97 controls	Mean 43	IgG ELISA	Current asthma diagnosed by ATS guidelines	Asthma: 1.55 (0.83 to 2.90)
Jun, 2005 (57)	Japan	46 cases with asthma, and 48 healthy controls	Mean 52	IgG ELISA IgG CagA	Current asthma diagnosed by ATS guidelines	Compared with healthy controls, Asthma: 1.10 (0.45 to 2.69) For CagA+, Asthma: 1.20 (0.39 to 3.69)



Criterion		References
Somatostatin production	↑	74
Gastrin release	↓	75
Gastric acidity	↑	76
Leptin production	?	73
Ghrelin production	↑	38
T-regulatory cell populations	↓	33-36

Figure 1 Changes in gastric physiology as the ancient (*H pylori*-colonised) stomach is becoming the post-modern (*H pylori*-free) stomach. Representative references are cited.

First, if *H pylori* is actually protecting against GORD,¹⁰ it also could protect against asthma, since some proportion of asthma is due to GORD;⁶⁸ this component may actually be underestimated.⁶⁹ However, this mechanism is unlikely to be sufficient to explain protective *H pylori* effects in hay fever and atopic dermatitis.

Second, the constellation of asthma, atopy, hay fever and skin sensitisation suggests immunological mediation. *H pylori*-positive persons have a gastric population of immunocytes, including regulatory T cells,³³⁻³⁶ that is largely or completely absent from *H pylori*-negative subjects. Such cells may have systemic immunomodulatory activities. Recent studies indicate an interaction of *H pylori* colonisation with *Mycobacterium tuberculosis*, with colonisation associated with the maintenance of tuberculosis latency,⁷⁰ again pointing to a global immunomodulatory role.

A third mechanism may relate to the effects of *H pylori*-induced inflammation on gastric hormonal levels.⁹ Both leptin and gastrin have immunomodulatory activities as well as intermediary effects on energy homeostasis.^{71 72} There is increasing evidence that *H pylori* gastric colonisation affects both ghrelin and leptin production^{38 73} which thus would affect the immunoregulatory environment.

Finally, the effects of *H pylori* on the autonomic nervous system might play a

role. Individual differences in the host-microbial interaction could account for differential risk and disease expression. Prospective studies that evaluate the influence of *H pylori* on both indicators of causal intermediates and asthma risk will help delineate the mechanisms.

CONCLUSIONS

For probably the first time in human history, generations of children are growing without *H pylori* in their stomachs, guiding the development of their immunological capabilities, their hormonal regulation of energy homeostasis, and their regulation of gastric acidity (fig 1). The loss of this ancient, dominant and persistent member of the normal biota of humans would be predicted to have consequences, and now there is much information about the beneficial and deleterious aspects of this change on gastrointestinal tract health and disease.^{1 10 77 78} However, increasing evidence is pointing to extra-intestinal manifestations of the disappearance of *H pylori*, including disorders of energy homeostasis^{38 39} and asthma. An inverse association of *H pylori* and childhood asthma, allergic rhinitis and atopy is becoming increasingly obvious. Although this may represent an epiphenomenon as part of a more general change in human microecology,¹ there is substantial biological plausibility for a role of the disappearance of *H pylori* and the rise of these allergic disorders of

children. Nevertheless, if *H pylori*, and especially *cagA* status, only is a marker for asthma risk, it could become useful for clinical and epidemiological studies. These questions are of sufficient importance that confirmatory and prospective studies in different populations should be carried out.

Clearly, the interactions of *H pylori* are complex, somewhat host-specific, and certainly incompletely understood. Ten years ago, one of us predicted that doctors of the future will have the tools to perform relevant phenotyping and genotyping of young children and then take the appropriate stocks of *H pylori* from their pharmacy and deliberately colonise that child with that strain (or combination of strains) most likely to optimise their life-long health.⁷⁹ The continuing beneficial associations of *H pylori* with reduction of risk for oesophageal diseases (including malignancy), now with asthma and atopy, and possibly with obesity and diabetes,^{9 38 39} should be considered in *H pylori* treatment and intervention plans, and move that earlier prediction closer to reality.

It is possible that for most individuals, *H pylori* is beneficial in childhood and more deleterious later in life. Within such a paradigm, a public health framework for *H pylori* introduction and eradication can be envisioned.

Acknowledgements: The authors thank Michael Marmor, Maria-Elena Fernandez-Beros, Linda Rogers, and Guillermo Perez-Perez for their participation in the initial studies at Bellevue Hospital that stimulated this work.

Funding: This research was supported by grant ES000260 from the National Institute of Environmental Health Sciences, grant CA016087 from the National Cancer Institute, grant RO1GM63270 from the National Institutes of Health, the Diane Belfer Program in Human Microbial Ecology, the Senior Scholar Award of the Ellison Medical Foundation, Ellison Medical Foundation, and Colten Family Foundation.

Competing interests: Dr Blaser, as a co-discoverer of *cagA* at Vanderbilt University, can receive royalties from the commercial exploitation of *cagA*. No diagnostic tests for *cagA* are currently licensed.

Revised 4 December 2007

Accepted 11 December 2007

Published Online First 14 January 2008

Gut 2008;57:561-567. doi:10.1136/gut.2007.133462

REFERENCES

1. Blaser MJ. Who are we? Indigenous microbes and the ecology of human diseases. *EMBO Rep* 2006;7:956-60.
2. Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. *Clin Microbiol Rev* 2006;19:449-90.
3. Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. *Proc Natl Acad Sci USA* 2006;103:732-7.

Leading article

4. **Linz B**, Balloux F, Moodley Y, *et al*. An African origin for the intimate association between humans and *Helicobacter pylori*. *Nature* 2007;**445**:915–8.
5. **Malaty HM**, El Kasabany A, Graham DY, *et al*. Age at acquisition of *Helicobacter pylori* infection: a follow-up study from infancy to adulthood. *Lancet* 2002;**359**:931–5.
6. **Parsonnet J**, Shmueli H, Haggerty TD. Fecal and oral shedding of *Helicobacter pylori* from healthy, infected adults. *JAMA* 1999;**282**:2240–5.
7. **Taylor DN**, Blaser MJ. The epidemiology of *Helicobacter pylori* infection. *Epidemiol Rev* 1991;**13**:42–59.
8. **Odenbreit S**, Puls J, Sedlmaier B, *et al*. Translocation of *Helicobacter pylori* CagA into gastric epithelial cells by type IV secretion. *Science* 2000;**287**:1497–500.
9. **Blaser MJ**, Atherton JC. *Helicobacter pylori* persistence: biology and disease. *J Clin Invest* 2004;**113**:321–33.
10. **Peek RM**, Blaser MJ. *Helicobacter pylori* and gastrointestinal tract adenocarcinomas. *Nat Rev Cancer* 2002;**2**:28–37.
11. **Barnard AJ**, ed. *Hunter–gatherers in history, archeology and anthropology*. Oxford: Berg 2004:278.
12. **Blaser MJ**, Kirschner D. The equilibria that permit bacterial persistence in human hosts. *Nature* 2007;**449**:843–9.
13. **Romero-Gallo J**, Perez-Perez GI, Novick RP, *et al*. Responses to *Helicobacter pylori* whole cell and CagA antigens amongst Ladakh patients undergoing endoscopy. *Clin Diag Lab Immunol* 2002;**9**:1313–7.
14. **Ghose C**, Perez-Perez GI, van Doorn LJ, *et al*. High frequency of gastric colonization with multiple *Helicobacter pylori* strains in Venezuelan subjects. *J Clin Microbiol* 2005;**43**:2635–41.
15. **Banatvala N**, Mayo K, Megraud F, *et al*. The cohort effect and *Helicobacter pylori*. *J Infect Dis* 1993;**168**:219–21.
16. **Kosunen TU**, Aromaa A, Knekt P, *et al*. *Helicobacter* antibodies in 1973 and 1994 in the adult population of Vammala, Finland. *Epidemiol Infect* 1997;**119**:29–34.
17. **Perez-Perez GI**, Salomaa A, Kosunen TU, *et al*. Evidence that cagA(+) *Helicobacter pylori* strains are disappearing more rapidly than cagA(–) strains. *Gut* 2002;**50**:295–8.
18. **Goodman K**, Correa P, Tenganá Aux HJ, *et al*. *Helicobacter pylori* infection in the Colombian Andes: a population-based study of transmission pathways. *Am J Epidemiol* 1996;**144**:290–9.
19. **Goodman K**, Correa P. Transmission of *Helicobacter pylori* among siblings. *Lancet* 2000;**355**:358–62.
20. **Wunder C**, Churin Y, Winau F, *et al*. Cholesterol glucosylation promotes immune evasion by *Helicobacter pylori*. *Nat Med* 2006;**12**:1030–8.
21. **McCaig LF**, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. *JAMA* 2002;**287**:3096–102.
22. **Peterson WL**, Graham DY, Marshall B, *et al*. Clarithromycin as monotherapy for eradication of *Helicobacter pylori*: a randomized, double-blind trial. *Am J Gastroenterol* 1993;**88**:1860–4.
23. **Rauws EAJ**, Langenberg W, Houthoff HJ, *et al*. Campylobacter pyloridis-associated chronic active antral gastritis. *Gastroenterology* 1988;**94**:33–40.
24. **Warren JR**. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet* 1983;**1**:1273.
25. **Marshall BJ**, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984;**1**:1311–5.
26. **Blaser MJ**. *Helicobacter* are indigenous to the human stomach: duodenal ulceration is due to changes in gastric microecology in the modern era. *Gut* 1998;**43**:721–7.
27. **Nomura A**, Stemmerman GN, Chyou P-H, *et al*. *Helicobacter pylori* infection and the risk for duodenal and gastric ulceration. *Ann Intern Med* 1994;**120**:977–81.
28. **Nomura AMY**, Perez-Perez GI, Lee J, *et al*. Relationship between *H. pylori* cagA status and risk of peptic ulcer disease. *Am J Epidemiol* 2002;**155**:1054–9.
29. **Parsonnet J**, Hansen S, Rodriguez L, *et al*. *Helicobacter pylori* infection and gastric lymphoma. *N Engl J Med* 1994;**330**:1267–71.
30. **Blaser MJ**, Pérez-Pérez GI, Kleanthous H, *et al*. Infection with *Helicobacter pylori* strains possessing cagA associated with an increased risk of developing adenocarcinoma of the stomach. *Cancer Res* 1995;**55**:2111–5.
31. **Rosebury T**. *Microorganisms indigenous to man*. New York: McGraw Hill, 1962: 1–8.
32. **Blaser MJ**. Pathogenesis and symbiosis: Human gastric colonization by *Helicobacter pylori* as a model system of amphibiosis. In: *Ending the war metaphor: the changing agenda for unraveling the host–microbe relationship*. Institute of Medicine. Washington, DC: National Academies Press, 2006: 115–30.
33. **Lundgren A**, Suri-Payer E, Enarsson K, *et al*. *Helicobacter pylori*-specific CD4+CD25high regulatory T cells suppress memory T-cell responses to *H. pylori* in infected individuals. *Infect Immun* 2003;**71**:1755–62.
34. **Rad R**, Brenner L, Bauer S, *et al*. CD25+Foxp3+ T cells regulate gastric inflammation and *Helicobacter pylori* colonization in vivo. *Gastroenterology* 2006;**131**:525–37.
35. **Lundgren A**, Stromberg E, Sjoling A, *et al*. Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in *Helicobacter pylori*-infected patients. *Infect Immun* 2005;**73**:523–31.
36. **Goll R**, Gruber F, Olsen T, *et al*. *Helicobacter pylori* stimulates a mixed adaptive immune response with a strong T-regulatory component in human gastric mucosa. *Helicobacter* 2007;**12**:185–92.
37. **Mattsson A**, Lönnroth H, Quiding-Järbrink M, *et al*. Induction of B cell responses in the stomach of *Helicobacter pylori*-infected subjects after oral cholera vaccination. *J Clin Invest* 1998;**102**:51–6.
38. **Nwokolo CU**, Freshwater DA, O'Hare P, *et al*. Plasma ghrelin following cure of *Helicobacter pylori*. *Gut* 2003;**52**:637–40.
39. **Marini E**, Maldonado A, Cabras S, *et al*. *Helicobacter pylori* and intestinal parasites are not detrimental to the nutritional status of Amerindians. *Am J Trop Med Hyg* 2007;**76**:534–40.
40. **Eder W**, Ege MJ, von Mutius E. The asthma epidemic. *N Engl J Med* 2006;**355**:2226–35.
41. **Strachan DP**. Hay fever, hygiene, and household size. *BMJ* 1989;**299**:1259–60.
42. **Matricardi PM**, Rosmini F, Panetta V, *et al*. Hay fever and asthma in relation to markers of infection in the United States. *J Allergy Clin Immunol* 2002;**110**:381–7.
43. **Matricardi PM**, Rosmini F, Riondino S, *et al*. Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. *BMJ* 2000;**320**:412–7.
44. **Kosunen TU**. Increase of allergen-specific immunoglobulin E antibodies from 1973 to 1994 in a Finnish population and a possible relationship to *Helicobacter pylori* infections. *Clin Exp Allergy* 2002;**32**:373–8.
45. **McCune A**, Lane A, Murray L, *et al*. Reduced risk of atopic disorders in adults with *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol* 2003;**15**:637–40.
46. **Linneberg A**. IgG antibodies against microorganisms and atopic disease in Danish adults: the Copenhagen Allergy Study. *J Allergy Clin Immunol* 2003;**111**:847–53.
47. **Jarvis D**, Luczynska C, Chinn S, *et al*. The association of hepatitis A and *Helicobacter pylori* with sensitization to common allergens, asthma and hay fever in a population of young British adults. *Allergy* 2004;**59**:1063–7.
48. **Radon K**. Farming exposure in childhood, exposure to markers of infections and the development of atopy in rural subjects. *Clin Exp Allergy* 2004;**34**:1178–83.
49. **von Hertzen LC**, Laatikainen T, Makela MJ, *et al*. Infectious burden as a determinant of atopy — a comparison between adults in Finnish and Russian Karelia. *Int Arch Allergy Immunol* 2006;**140**:89–95.
50. **Janson C**. The effect of infectious burden on the prevalence of atopy and respiratory allergies in Iceland, Estonia, and Sweden. *J Allergy Clin Immunol* 2007;**120**:673–9.
51. **Chen Y**, Blaser MJ. Inverse associations of *Helicobacter pylori* with asthma and allergy. *Arch Intern Med* 2007;**167**:821–7.
52. **Herbarth O**, Bauer M, Fritz GJ, *et al*. *Helicobacter pylori* colonisation and eczema. *J Epidemiol Community Health* 2007;**61**:638–40.
53. **Shiotani A**, Miyanishi T, Kamada T, *et al*. *Helicobacter pylori* infection and allergic diseases: Epidemiological study in Japanese university students. *J Gastroenterol Hepatol* 2007; doi:10.1111/j.1440-1746.2007.05107x.
54. **Chen Y**, Blaser M. *Helicobacter pylori* colonization is inversely associated with childhood asthma. Abstract LB-1 presented at the 45th Annual Meeting of Infectious Diseases Society of America. San Diego, California, October 2007. Available at <http://www.idsociety.org>. *J Infect Dis* 2008; (in press).
55. **Bodner C**, Anderson WJ, Reid TS, *et al*. Childhood exposure to infection and risk of adult onset wheeze and atopy. *Thorax* 2000;**55**:383–7.
56. **Tsang KW**, Lam WK, Chan KN, *et al*. *Helicobacter pylori* sero-prevalence in asthma. *Respir Med* 2000;**94**:756–9.
57. **Jun ZJ**, Lei Y, Shimizu Y, *et al*. *Helicobacter pylori* seroprevalence in patients with mild asthma. *Tohoku J Exp Med* 2005;**207**:287–91.
58. **Reibman J**, Marmor M, Fernandez-Beros M, *et al*. Asthma in an urban population is inversely associated with *Helicobacter pylori* status. Abstract presented at the American Thoracic Society, May 2005. Abstract can be request at <http://www.thoracic.org/>.
59. **National Center for Health Statistics**. *Plan and operation of the Third National Health and Nutrition Examination Survey. 1988–94*. Vital and Health Statistics, series 1, no. 32. Hyattsville, MD: National Center for Health Statistics, 1994.
60. **National Center for Health Statistics**. *NHANES 1999–2000 data files-data, docs, codebooks, SAS code*. Hyattsville, MD: National Center for Health Statistics, 2005.
61. **Hill AB**. The environment and disease: association or causation? *Proc Soc Med* 1965;**58**:295–300.
62. **Vonk JM**, Postma DS, Boezen HM, *et al*. Childhood factors associated with asthma remission after 30 year follow up. *Thorax* 2004;**59**:925–9.
63. **Arif AA**, Whitehead LW, Delclos GL, *et al*. Prevalence and risk factors of work related asthma by industry among United States workers: data from the third national health and nutrition examination survey (1988–94). *Occup Environ Med* 2002;**59**:505–11.
64. **Butland BK**, Strachan DP. Asthma onset and relapse in adult life: the British 1958 birth cohort study. *Ann Allergy Asthma Immunol* 2007;**98**:337–43.
65. **Kozyrskyj AL**, Ernst P, Becker AB. Increased risk of childhood asthma from antibiotic use in early life. *Chest* 2007;**131**:1753–9.
66. **Spiro DM**, Arnold DH, Barbone F. Association between antibiotic use and primary idiopathic intussusception. *Arch Pediatr Adolesc Med* 2003;**157**:54–9.
67. **Pillinger MH**, Marjanovic N, Kim S-Y, *et al*. *Helicobacter pylori* stimulates gastric epithelial cell MMP-1 secretion via CagA-dependent and independent ERK activation. *J Biol Chem* 2007;**282**:18722–31.
68. **Simpson WG**. Gastroesophageal reflux disease and asthma: diagnosis and management. *Arch Intern Med* 1995;**155**:798–803.
69. **Field SK**, Underwood M, Brant R, *et al*. Prevalence of gastroesophageal reflux symptoms in asthma. *Chest* 1996;**109**:316–22.
70. **Perry S**, de Jong BC, Hill P, *et al*. *Helicobacter pylori* and the outcome of *M. tuberculosis* infection. Abstract LB-22 presented at the 45th Infectious Diseases Society of America. Annual Meeting, San Diego, CA, 4–7 October 2007 (page 256 Program and Abstracts). Available at <http://www.idsociety.org/>.
71. **Matrese G**, Moschos S, Mantzoros CS. Leptin in immunology. *J Immunol* 2005;**174**:3137–42.

72. **Matsuda Y**, Okamatsu H, Tani K, *et al*. Correlation of plasma ghrelin and serum immunoglobulin levels: a hormonal link between immunity and obesity? *J Allergy Clin Immunol* 2007;**119**:S174.
73. **Azuma T**, Suto H, Ito Y, *et al*. Gastric leptin and *Helicobacter pylori* infection. *Gut* 2001;**49**:324–9.
74. **Moss SF**, Legon S, Bishop AE, *et al*. Effect of *Helicobacter pylori* on gastric somatostatin in duodenal ulcer disease. *Lancet* 1992;**340**:930–2.
75. **Levi S**, Beardshall K, Haddad G, *et al*. *Campylobacter pylori* and duodenal ulcers: the gastrin link. *Lancet* 1989;**1**:1167–8.
76. **El-Omar EM**, Penman ID, Ardill JE, *et al*. *Helicobacter pylori* infection and abnormalities of acid secretion in patients with duodenal ulcer disease. *Gastroenterology* 1995;**109**:681–91.
77. **Kuipers EJ**, Uytendaele AM, Pena AS, *et al*. Long-term sequelae of *Helicobacter pylori* gastritis. *Lancet* 1995;**345**:1525–8.
78. **Blaser MJ**, Nomura A, Lee J, *et al*. Early life family structure and microbially-induced cancer risk. *PLOS Medicine* 2007;**4**:e7.
79. **Blaser MJ**. Science, medicine, and the future: *Helicobacter pylori* and gastric diseases. *BMJ* 1998;**316**:1507–10.

Editor's quiz: GI snapshot

Robin Spiller, editor

An infrequent cause of acute left lower quadrant abdominal pain

CLINICAL PRESENTATION

A 65-year-old male patient referred with acute abdominal pain in the left lower quadrant and a low grade fever (38°C) was admitted to the surgical emergency department of our institution. He was haemodynamically stable. His bowel movements were completely normal. Physical examination demonstrated localised tenderness in the left iliac fossa, but there was no peritonism. Serological studies revealed no abnormality apart from a white blood cell (WBC) count of $12 \times 10^9/l$ and C-reactive protein (CRP; 3.0 mg/l). As a first step, abdominal and bowel ultrasound (US) without oral contrast agent was performed. A relevant US finding was the appearance of a well-delineated echogenic mass with a peripheral hypoechoic rim in the left flank; this lesion appeared small, oval and non-compressible, located anteromedial to the left colon with perienteric hypertrophied mesenteric adipose tissue, and absence of vascular flow on colour Doppler sonography (fig 1). Subsequent CT examination allowed the correct diagnosis to be made (fig 2).

QUESTIONS

What is the differential diagnosis? What radiological abnormalities are seen and what is the most likely diagnosis?

See page 622 for answers.

This case is submitted by:

S Greco,¹ G Maconi,¹ E Bareggi,¹ E Radice,¹ G Bianchi Porro,¹ A Norsa²




Figure 1 Ultrasound appearance of a non-compressible, oval, well-delineated echogenic mass with a peripheral hypoechoic rim (double arrows), located anteromedial to the left colon (curved arrow) with perienteric mesenteric fat proliferation visualised with a convex probe. Informed consent was obtained for publication of this figure.

¹Clinical Science Department, Gastroenterology Unit, "L. Sacco" University Hospital, Milan, Italy; ²Radiology, "L. Sacco" University Hospital, Milan, Italy

Correspondence to: Dr Salvatore Greco, Clinical Science Department, Gastroenterology Unit, "L. Sacco" University Hospital, Via G.B. Grassi, 74, 20157 Milan, Italy; salvatore.greco@unimi.it

Patient consent: Informed consent was obtained for publication of the person's details in this report.

Gut 2008;**57**:567. doi:10.1136/gut.2006.119248

Figure 2 Axial (A) and reconstructed coronal image (B) from a contrast-enhanced CT enteroclysis showing (arrow) a fat density lesion that has a hyperattenuating rim with surrounding inflammation abutting the sigmoid colon–descending colon junction. Informed consent was obtained for publication of this figure.

